Cardiovascular disease in diabetes

Diabetes Care

Volumn 31, Issue 6, 2008, Pages 1260-1266

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN B; CLOPIDOGREL; DIPYRIDAMOLE; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MULTIVITAMIN; NICOTINIC ACID; PIOGLITAZONE; ROSIGLITAZONE; SELENIUM; SILDENAFIL; SIMVASTATIN; SULFONYLUREA; TICLOPIDINE; TORCETRAPIB; CALCIUM; LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FOOD AND DRUG ADMINISTRATION; HEARING LOSS; HEART INFARCTION; HUMAN; ISCHEMIC OPTIC NEUROPATHY; NEPHROTOXICITY; PRIAPISM; SEXUAL BEHAVIOR; SIDE EFFECT; STROKE; THROMBOEMBOLISM; BLOOD; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; ELECTROCARDIOGRAPHY; NOTE;

APOLIPOPROTEINS B; CALCIUM; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; ELECTROCARDIOGRAPHY; HUMANS; LIPOPROTEINS, LDL; STROKE;

EID: 48649094962     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-zb06     Document Type: Article

References (62)

1. Haffner SM, Lehto S, Rönnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
2. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE, the Detection of Ischemia in Asymptomatic Diabetics Investigators: Detectionofsilent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 27:1954-1961, 2004
3. Libby P, Plutzky J: Diabetic macrovascu- lar disease: the glucose paradox? Circulation 106:2760-2763, 2002
4. American Diabetes Association: Standards of medical care in diabetes-2008 (Position Statement). Diabetes Care 31 (Suppl. 1):S12-S54, 2008
5. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chait- man BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503-1516, 2007
6. Albers AR, Krichavsky MZ, Balady GJ: Stress testing in patients with diabetes mellitus: diagnostic and prognostic value. Circulation 113:583-592, 2006
7. Cheng YJ, Lauer MS, Earnest CP, Church TS, Kampert JB, Gibbons LW, Blair SN: Heart rate recovery following maximal exercise testing as a predictor of cardiovascular disease and all-cause mortality in men with diabetes. Diabetes Care 26: 2052-2057, 2003
8. Sorajja P, Chareonthaitawee P, Rajago- palan N, Miller TD, Frye RL, Hodge DO, Gibbons RJ: Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation 112: I311-I316, 2005
9. Raggi P, Bellasi A, Ratti C: Ischemia imaging and plaque imaging in diabetes: complementary tools to improve cardiovascular risk management. Diabetes Care 28:2787-2794, 2005
10. Kilpatrick ES, Rigby AS, Atkin SL: Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 51:365-371, 2008
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and micro- vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
12. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421-31, 2004
13. Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, von Herrath MG, Chait A, Bornfeldt KE: Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 114:659-668, 2004
14. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837-853, 1998
15. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
16. Nissen SE, Wolski K: Effect of rosiglita- zone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007
17. Diamond GA, Bax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147:578-581, 2007
18. Bloomgarden ZT: The Avandia debate. Diabetes Care 30:2401-2408, 2007
19. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180-1188, 2007
20. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta- analysis of randomised clinical trials. Lancet 370:1129-1136, 2007
21. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52:1210-1214, 2003
22. Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24:447-453, 2001
23. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
24. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Ar- mitage J, Baigent C: Efficacy of cholesterol- lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117-125, 2008
25. PurnellJQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 280:140-146, 1998
26. Nathan DM, Cleary PA, Backlund JY, Ge- nuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl JMed 353:2643-2653, 2005
27. LaRosaJC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435, 2005
28. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162:2597-2604, 2002
29. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, the FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861, 2005
30. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and nia- cin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001
31. Canner PL, Berge KG, Wenger NK, Stam- ler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: longterm benefit with niacin. J Am Coll Cardiol 8: 1245-1255, 1986
32. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122, 2007
33. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, ElkonK, MarcovinaS, RidkerP, Oram JF, Heinecke JW: Shotgun proteomics implicates protease inhibition and complement activation in the anti- inflammatory properties of HDL. J Clin Invest 117:746-756, 2007
34. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R, the Systolic Hypertension in Europe Trial Investigators: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340:677-684, 1999
35. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the (HOT) randomised trial. Lancet 351:1755-1762, 1998
36. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
37. Harpaz D, Gottlieb S, Graff E, Boyko V, Kishon Y, Behar S, the Israeli Bezafibrate Infarction Prevention Study Group: Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Am J Med 105:494-9, 1998
38. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106, 1994
39. Despres JP, Lemieux I, Prud'homme D: Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 322:716-720, 2001
40. Manson JE, Skerrett PJ, Greenland P, VanItallie TB: The escalating pandemics of obesity and sedentary lifestyle: a call to action for clinicians. Arch Intern Med 164: 249-258, 2004
41. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
42. Bloomgarden ZT: Dyslipidemia and the metabolic syndrome. Diabetes Care 27: 3009-3016, 2004
43. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ ten-country panel. J Intern Med 259: 247-258, 2006
44. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PWF, D'Agostino RBL: DL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management. J Clin Lipidol 1:583-592, 2007
45. Lindahl B, Dinesen B, Eliasson M, Røder M, Hallmans G, Stegmayr B: High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke 31:2936-2941, 2000
46. Gertler MM, Leetma HE, Koutrouby RJ, Johnson ED: The assessment of insulin, glucose and lipids in ischemic thrombotic cerebrovascular disease. Stroke 6:77-84, 1975
47. Pyörälä M, Miettinen H, Laakso M, Pyörälä K: Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke 29:1860-1866, 1998
48. Folsom AR, Rasmussen ML, Chambless LE, Howard G, Cooper LS, Schmidt MI, Heiss G, the Atherosclerosis Risk in Communities (ARIC) Study Investigators: Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care 22: 1077-1083, 1999
49. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, McVeetyJC, Horwitz RI: Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke. Neurology 60:1447-1451, 2003
50. Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, Wright C, Giardina EG, DiTullio MR, Homma S, Paik MC: Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 39:30-35, 2008
51. Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet 367:606 -617, 2006
52. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabate M, Jimenez- Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430-2435, 2005
53. Hass WK, Easton JD, Adams HP Jr, Pryse- Phillips W, Molony BA, Anderson S, Kamm B, the Ticlopidine Aspirin Stroke Study Group: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321:501-507, 1989
54. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367:1665-1673, 2006
55. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329 - 1339, 1996
56. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-GuiuJ, Rupprecht HJ; MATCH investigators: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:331-337, 2004
57. Pyǒrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614-620, 1997
58. Yusuf S, Sleight P, PogueJ, BoschJ, Davies R, Dagenais G, the Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
59. Lindholm LH, Dahlof B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, Snapinn S, Wachtell K; LIFE studygroup: Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 362:619 -620, 2003
60. Goede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591, 2008
61. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dor- mandy J; PROactive Investigators: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pio- glitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865-873, 2007
62. Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, Weih M, Dirnagl U: Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 38: 2526 -2530, 2007